Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

NoStop: Personalised Small Molecule Gene Therapy

Cel

Premature termination codons (PTCs) account for 10–20% of genetic disease cases and represent a major mechanism of tumor suppressor gene inactivation. A therapeutic approach capable of reverting PTCs into sense codons would have broad applicability, benefiting millions of patients across diverse genetic disorders and cancers. Readthrough therapy offers this potential; however, its clinical impact has so far been limited by disappointing trial outcomes.
Using a combination of in-house–developed high-throughput human readthrough assays and machine learning, we recently demonstrated that a key factor underlying this limited success is the strong sequence specificity of readthrough drugs, which varies markedly among compounds. With the NoStop platform, our goal is to build on this validated technology to transform the readthrough therapy field by systematically generating comprehensive PTC-specificity maps for all known readthrough compounds, while simultaneously establishing a sequence-tailored high-throughput drug discovery pipeline to identify novel proprietary readthrough drugs. If successful, NoStop will generate invaluable data to enable the transition of readthrough therapy from a one-size-fits-all approach to a personalized medicine paradigm.

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

System finansowania

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) ERC-2025-POC

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Instytucja przyjmująca

FUNDACIO CENTRE DE REGULACIO GENOMICA
Wkład UE netto
€ 107 000,00
Koszt całkowity
Brak danych

Beneficjenci (2)